Latest Taxation News

Careteq Limited has agreed to sell its Embedded Health Solutions business for $5 million, aiming to strengthen its balance sheet and focus on expanding its home medication review platform amid ongoing tax disputes.

BlackRock Investment Management (Australia) Limited has announced the Distribution Reinvestment Plan prices for four key iShares ETFs for the January 2026 distribution period, providing clarity for investors opting to reinvest their dividends.

BlackRock Investment Management (Australia) Limited has announced confirmed cash distributions for four Australian iShares ETFs, detailing payment schedules and reinvestment options for investors.

BlackRock Investment Management (Australia) Limited has announced estimated cash distributions for four Australian iShares ETFs, outlining key dates and options for investors to reinvest dividends.

Arena REIT has announced its December 2025 quarter distribution of 4.8125 cents per stapled security, reflecting steady income from its social infrastructure portfolio. The distribution includes components relevant for tax purposes, underscoring the REIT’s ongoing compliance and investor transparency.

FireFly Metals has agreed to sell its Ontario gold assets to Bellavista Resources for up to A$86.1 million in shares and performance rights, unlocking value for shareholders while focusing on its copper-gold growth strategy.

Betashares Capital Ltd has announced the final distribution amounts for January 2026 across a broad suite of ETFs listed on the ASX AQUA market, detailing payment schedules and reinvestment options.

Astron Limited has advanced its Donald Rare Earth and Mineral Sands Project with conditional senior debt support and ongoing financing discussions, targeting a final investment decision by the end of March 2026.

Recce Pharmaceuticals progresses its Phase 3 diabetic foot infection trial in Indonesia, reports promising preclinical data for inhaled RECCE 327, and secures significant R&D funding and patent protection.

Careteq Limited reported a disciplined operating cash flow in Q2 FY26 with strong growth in its Embedded Health Solutions segment and ongoing resolution of an ATO tax incentive dispute.

Latrobe Magnesium has resolved a critical manufacturing defect at its Demonstration Plant, enabling Magnesium Oxide production to resume, while securing key financial support for its commercial expansion plans.

Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.